Not yet recruitingPriority 4 · Lower priorityNCT07467317

BV-CHP Real-life and Biological Evidences in Patients With sALCL

Plain-language summary

This trial is evaluating a new treatment as a treatment for people newly diagnosed with anaplastic large cell lymphoma (ALCL). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

Age 18 Years or older
Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length: Ask the trial team for details
Visit frequency: Ask the trial team for details

TrialCompass — Clinical Trial Summary

BV-CHP Real-life and Biological Evidences in Patients With sALCL

NCT07467317

Phase: | Status: Not yet recruiting | Priority: Lower

Plain-language summary

Who can join

Age 18 Years or older
Newly diagnosed, not yet treated

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 100 patients

Primary endpoint: To evaluate the progression free survival (PFS)

Ages: 18 Years to —

Start date: 2026-05 | Est. completion: 2028-05

Locations

0 US sites · 19 total

Contact

Uffici Studi FIL | startup@filinf.it | +390131033153

Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07467317

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.